Implementing Pre-emptive Germline Genomic Testing for Preventive Medicine

Program Committee Moderator(s)

• 

  Sherin Shaaban, MD, PhD, FACMG

  Associate Professor of Pathology/Medical director of pharmacogenetics and molecular genetics
  University of Utah
  Salt Lake City, Utah, United States

Co-Moderator (Early Career)(s)

• 

  Hannah Wollenzien, PhD (she/her/hers)

  Assistant Clinical Laboratory Director
  Sanford Health
  Sioux Falls, South Dakota, United States

Description: The continued growth of knowledge on germline variation and how it can impart certain health risks has prompted the availability of genetic testing as a preventive medicine intervention. Notable examples include the optional return of ACMG secondary findings during clinical exome/genome testing, pharmacogenomic testing, and polygenic risk score testing. Although all these forms of testing are currently available for providers through traditional clinical workflows, this session is aimed at reviewing how these forms of testing can be leveraged for more innovative genomic screening in the context of larger preventative medicine programs.

If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)

Title: Germline Testing in Cancer Patients: Molecular Diagnostic Considerations and Clinical Implications
Please Click Here to Learn More.

Presentations:

• 1:15 PM - 1:45 PM EST

  Opportunities and Challenges With Implementing ACMG Secondary Findings
  

  Breakout Speaker: David T Miller, MD, PhD (he/him/his) – Boston Children's Hospital
• 1:45 PM - 2:15 PM EST

  Navigating Ethical Issues in Implementing Polygenic Risk Score Screening
  

  Breakout Speaker: Anna C F Lewis, PhD (she/her/hers) – Brigham and Women's Hospital
• 2:15 PM - 2:45 PM EST

  Opportunities/Challenges of Implementing Pre-emptive Pharmacogenomic Testing
  

  Breakout Speaker: Peter H. O'Donnell, MD – The University of Chicago